AzTrials
AzTrials

Depression DisordersNCT07070531

Unified Protocol in Penitentiary Facilities

A study testing Unified Protocol in people with Depression Disorders and Anxiety, run by Instituto de Investigación Sanitaria Aragón at 1 site in Spain.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Emotional disorders (EDs), which include anxiety disorders, unipolar mood disorders, and other related conditions, exhibit a high prevalence within prison populations, significantly exceeding that of the general population. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depression Disorders, Anxiety, Mood Disorders
What is being tested?
Unified Protocol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteSpain
Study dates
1 Nov 2025to 1 Jul 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • At least one emotional disorder diagnosis (e.g., anxiety, depression, OCD, trauma-related, somatic, dissociative) based on the MINI interview
  • Comprehension of the intervention language (Spanish or Catalan)
  • Substance abstinence for more than 1 month
  • Voluntary participation and availability for all assessment and treatment sessions
  • Stable pharmacological treatment during the study unless medically contraindicated
  • Signed informed consent

Who cannot join

  • No emotional disorder diagnosis
  • Cognitive impairment or IQ <70 preventing comprehension
  • Diagnosis of a mental disorder incompatible with group formats (e.g., histrionic personality disorder)
  • Suicide risk at assessment
  • Legal status involving potential release or leave that could affect adherence

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Óscar Peris Baquero, Phd contact

978645386 ext. +34

operis@unizar.es

Spain1 site
  • Universidad de Zaragoza

    Teruel, Teruel, 44003

    Óscar Peris Baquero, Phd, 978645386 ext. +34, operis@unizar.es

Other trials in Spain

About this study

Official title: Feasibility and Clinical Utility Study of the Unified Protocol for Group Treatment of Emotional Disorders in Penitentiary Facilities

Emotional disorders (EDs), which include anxiety disorders, unipolar mood disorders, and other related conditions, exhibit a high prevalence within prison populations, significantly exceeding that of the general population. Despite the high incidence of these disorders, the resources available for their treatment in correctional facilities are limited. The shortage of both human and material resources hinders inmates' access to quality mental health care.

In this context, the Unified Protocol (UP) for the transdiagnostic treatment of emotional disorders, a transdiagnostic intervention grounded in Cognitive Behavioral Therapy, has demonstrated effectiveness in addressing a variety of psychological problems across different contexts. It has also proven to be cost-effective, particularly when delivered in a group format. Therefore, implementing the UP in group format within correctional settings could represent a viable strategy to optimize limited resources and provide accessible and effective treatment to a larger number of inmates.

Read more

The primary objective of this pilot study is to evaluate the feasibility and clinical utility of the UP for the treatment of emotional disorders in prison environments. To this end, the UP will be delivered to approximately 25 participants, organized into groups of six to eight individuals, each receiving 12 weekly sessions lasting one hour. Follow-up assessments will be conducted at one, three, and six months after the intervention.

A mixed-methods approach will be employed to analyze the results, combining quantitative analyses to assess changes in emotional symptomatology and qualitative analyses to explore participant satisfaction and therapist acceptance. It is expected that participants will experience statistically significant improvements in emotional symptoms and that these improvements will be sustained over time, up to the six-month follow-up. It is also anticipated that participants will report a high level of satisfaction with the treatment. Furthermore, therapists are expected to evaluate the intervention positively and to identify potential barriers to its implementation.

The results of this pilot study will contribute to improving the feasibility and clinical utility of the UP in correctional settings, while also laying the groundwork for a future randomized controlled trial involving a larger number of facilities, participants, and therapists.

Read the detailed description

Prevalence of Mental Disorders in the Prison Population

According to the World Health Organization, mental disorders are the most prevalent health condition in European penitentiary institutions, affecting 32.8% of the incarcerated population, with incidence rates continuing to rise. This trend is corroborated by numerous studies that have long highlighted the high prevalence of mental disorders among inmates, significantly surpassing rates observed in the general population. For instance, common mental disorders (e.g., anxiety and mood disorders) are reported to be twice as prevalent, while severe mental disorders (e.g., personality or psychotic disorders) are up to four times more prevalent among the incarcerated population.

In Spain, the 2022 Survey on Health and Drug Use in the Inmate Population revealed that 42.3% of incarcerated women and 34.3% of incarcerated men have been diagnosed with a psychological disorder at some point in their lives. The study found prevalence rates of 18% for depression, 9.3% for personality disorders, and 5.6% for bipolar disorder. Similar results have been reported in other studies, where 14% of diagnoses among inmates were related to mood and/or anxiety disorders, with 80% of cases showing comorbidity with more than one diagnosis.

Conceptualization of Emotional Disorders and Emotion Dysregulation

Despite the diversity of disorders encompassed by anxiety and mood disorders and their differing clinical manifestations, scientific literature supports their grouping under a single category termed Emotional Disorders (EDs), which includes anxiety disorders, unipolar mood disorders, trauma- and stressor-related disorders, and obsessive-compulsive and related disorders. It has been suggested that these disorders share common etiological and maintenance mechanisms, such as neuroticism-defined as the trait tendency to experience frequent and intense negative emotions along with the perception of the world as dangerous/unpredictable -low extraversion, described as the tendency to engage with the environment with energy, joy, sociability, and confidence, and difficulties in emotion regulation, understood as the process by which an individual can influence the emotions they experience, how they experience them, and how and when they express them. Scientific evidence indicates that individuals with EDs exhibit deficits in emotion regulation and tend to engage in maladaptive emotion regulation behaviors, such as avoiding places, situations, sensations, or thoughts that are unpleasant, aiming to reduce emotional distress. While this may be effective in the short term by decreasing emotional discomfort, in the medium and long term, it not only fails to resolve the problem but also exacerbates and perpetuates it over time.

Mental Health Care in Spanish Prisons

Despite the high prevalence of mental disorders in this context, penitentiary centers have limited human and material resources. Specifically, in 2020, the estimated ratio of prison doctors per 1,000 inmates in Spain was 5.2, below the European average of 8.0 doctors per 1,000 inmates, according to WHO data. Similarly, the ratios of psychology or psychiatry professionals in penitentiary centers fall below international recommendations, with estimated ratios in 2020 of 0.8 psychiatric specialists per 100 individuals, significantly lower than in other European countries such as Germany, France, Italy, and the United Kingdom, where the ratio is estimated at around 5 specialists per 100 incarcerated individuals. Due to the high demand for psychological assistance and limited human resources, there is a need for brief, intensive, and evidence-based group interventions to address EDs in the penitentiary context.

Approach to Mental Health Issues in the Penitentiary System

The approach to penitentiary healthcare varies across different regions in Spain. Currently, the only autonomous communities with competencies in this area are Catalonia, the Basque Country, and the Chartered Community of Navarre. In the rest of the national territory, at the state level, this responsibility falls under the General Secretariat of Penitentiary Institutions.

Regarding strategies for the penitentiary treatment of mental health in Spain, individuals with psychological disorders who are deprived of their liberty can receive assistance through two resources: Psychiatric Penitentiary Hospitals (PPHs), institutions under the General Secretariat of Penitentiary Institutions offering treatment during incarceration, and ordinary penitentiary centers, which house 80% of inmates with mental disorders. In 2009, the Mental Illness Care Program in Prison (PAIEM) was introduced, available in 64 of the 66 ordinary centers under the Ministry of the Interior for inmates with Severe Mental Disorders. This program includes activities related to social skills promotion, self-care, improved self-control, psychoeducation, relapse prevention, and preparation for release, among others. In 2022, these interventions recorded a total of 1,817 participants, representing 4.45% of the total incarcerated population in the country.

In recent years, new models of mental health care have emerged, particularly in Catalonia, where the approach to this health issue in prisons occurs in three different areas: psychiatric units, outpatient care through the Primary Support Program (PSP), and care for individuals in third-degree through the Individualized Penitentiary Service Program (PSI). Despite these efforts, the high prevalence of mental disorders among inmates and the lack of resources significantly hinder the implementation of specific, evidence-based intervention programs.

Currently, various initiatives are being implemented to address some of the issues present in the prison population, such as self-harming behaviors. An example is the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program, specifically designed to treat these behaviors. This group-based cognitive-behavioral therapeutic approach illustrates the feasibility of implementing structured group interventions in the penitentiary context.

However, given the high prevalence of EDs among inmates and the comorbidity present in these disorders, it is necessary to develop and implement transdiagnostic interventions aimed at improving emotion regulation skills across all EDs, not solely those exhibiting self-harming behaviors.

Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders and Intervention Formats

The categorical classification model of mental disorders has facilitated the development of various evidence-based psychological treatments targeting specific clinical syndromes described in the DSM or ICD manuals. Despite the benefits achieved thus far, psychopathological and clinical studies have highlighted the existence of shared etiological and maintenance mechanisms across different disorders and disorder groups, leading to the transdiagnostic approach. The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) is a manualized transdiagnostic intervention based on Cognitive Behavioral Therapy, focusing on addressing the etiological and maintenance mechanisms of EDs, such as neuroticism, worry, rumination, and emotion dysregulation, among others. The UP consists of eight modules that include training in five key emotion regulation skills: mindfulness, cognitive flexibility, counteracting emotion-driven behaviors, interoceptive exposure, and emotional exposure. Its modular nature enhances flexibility and adaptability to various clinical problems (e.g., women in fertility units or as a preventive measure for EDs in university students) and allows for cost-effective applications, such as group formats. To date, several systematic reviews and meta-analyses have supported the efficacy of the UP in treating individuals diagnosed with EDs, considering it a treatment of choice for these disorders.

In Spain, our research team has led a line of investigation focused on the evaluation, diagnosis, and treatment of EDs through the UP. In our country, the UP has proven to be an effective and cost-efficient intervention for treating EDs when applied in group format within specialized mental health units of the Public Health System. Specifically, in a multicenter randomized clinical trial involving 533 participants diagnosed with EDs, the UP was administered in 12 two-hour weekly sessions. The study's results indicated that changes in the UP treatment condition were comparable to those achieved with treatment as usual (non-structured individual cognitive-behavioral therapy), with greater improvements observed in depression, anxiety symptoms, and quality of life. Furthermore, the improvements in the UP condition were sustained over time (up to 12 months post-treatment), despite the intervention being delivered intensively over approximately three months, reflecting its long-term efficacy. Additionally, the project's findings demonstrated that, in the long term (12-month follow-up), the cost of treatment in the UP condition was lower than in the treatment-as-usual condition (€161.74, SD = 34.09, range €95.92-€299.75 vs. €183.50, SD = 77.52, range €71.94-€335.72, respectively), and high levels of participant satisfaction and strong acceptability among clinical professionals in public mental health units were also observed.

Finally, the UP has also been adapted to treat severe mental disorders, such as bipolar disorder and psychotic spectrum disorders. In the latter case, our research team has demonstrated its efficacy in individuals at high risk for psychosis. Positive outcomes have also been observed in patients with treatment-resistant schizophrenia, self-injurious behaviors, and suicidal ideation. Although some of these studies are pilot or single-case designs, the encouraging results in emotional symptoms, emotion regulation, and quality of life suggest that the UP may be a useful and complementary intervention in addressing emotional dysregulation, especially in more severe disorders. This opens up doors for further investigation into its efficacy. However, to date, no studies have examined the feasibility of the UP in the prison setting.

Study Rationale

The high prevalence of emotional disorders, along with their comorbidity with other severe mental illnesses in the prison population, presents a significant challenge due to the limited human and material resources in penitentiary centers. In this regard, the UP has proven to be an effective intervention across various contexts and emotional problems. For this reason, implementing the UP in a group format for the treatment of emotional disorders in prison settings could optimize available resources and provide a comprehensive approach to emotional disorders, improving inmates' mental health, comorbid symptomatology, and quality of life. To our knowledge, this will be the first study to test the feasibility and clinical utility of the UP for the group-based treatment of emotional disorders in prison settings, and its findings will lay the groundwork for the development of future controlled clinical trials.

Being tested
Unified Protocol
Keywords
Unified Protocol, Transdiagnostic Intervention, Incarcerated Population, Correctional Facilities, Group Therapy, Cognitive-behavioral Therapy, Emotional Disorders
Medical subject headings
Anxiety Disorders, Mood Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Unified ProtocolBehavioural

    The Unified Protocol (UP) is a transdiagnostic, emotion-focused cognitive-behavioral treatment designed to address a range of emotional disorders, including anxiety, depression, and related conditions. It targets core mechanisms such as emotional avoidance, cognitive rigidity, and maladaptive emotion regulation strategies. The UP consists of structured modules focused on increasing emotional awareness, cognitive flexibility, and exposure to emotionally evocative situations. By addressing common underlying processes across disorders, the UP enhances treatment efficiency and applicability in both individual and group formats. Its flexibility makes it suitable for diverse populations and settings, including community and clinical contexts.

Study groups in NCT07070531
Study groupRoleWhat they receive
Unified Protocol in group formatExperimentalParticipants will receive the intervention of the Unified Protocol (UP) in a group format, consisting of 12 sessions, one per week, each lasting 1 hour. Each session includes a review of previous content, resolution of doubts, and development of new material from one of eight modules. The program covers motivation for change, goal setting, understanding the adaptive function of emotions, emotional awareness and mindfulness, cognitive flexibility, problem solving, and addressing emotion-driven behaviors. Exposure to emotional and interoceptive experiences is introduced in later sessions. Follow-up sessions at 1, 3, and 6 months review progress, reinforce learning, identify risk signals, and promote relapse prevention and long-term well-being.
Receives: Behavioral: Unified Protocol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Structured interview for anxiety disorders and related disorders, according to the DSM-5 (ADIS-5)

    Diagnostic interview to determine if the participant has a clinical diagnosis of emotional disorder (ET) and can be part of the study. The following diagnoses according to the DSM-V are included within the category of emotional disorder: major depressive disorder, dysthymic disorder, panic disorder, agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, post-traumatic stress disorder, social anxiety disorder, hypochondria, and adjustment disorders. Patients with anxiety disorders not otherwise specified and those with depressive disorders not otherwise specified will also be included in the study.

    Measured: Only before of the treatment to check inclusion criteria

  2. General Depression Severity and Interference Scale (ODSIS)

    Severity of depressive symptoms; 5 items with 5-point Likert scale ranging from 0 (I did not feel depressed) to 4 (constant depression). Higher scores are associated with greater depressive symptomatology and interference.

    Measured: Up to 6 months follow-up

  3. General Severity and Interference Scale for Anxiety (OASIS)

    Severity of anxiety symptoms; 5 items with 5-point Likert scale ranging from 0 (I did not feel anxious) to 4 (constant anxiety). Higher scores are associated with greater anxiety symptomatology and interference.

    Measured: Up to 6 months follow-up

  4. Multidimensional Inventory for Emotional Disorders (MEDI)

    Evaluation through 49 items of the transdiagnostic profile of Emotional Disorders, which is composed of nine dimensions: neurotic temperament, positive temperament, depressed mood, somatic anxiety, arousal activation, social anxiety, intrusive cognitions, traumatic re-experiencing, and avoidance

    Measured: Up to 6 months follow-up

Secondary outcomes (4)
  1. Emotional Regulation Difficulties Scale (DERS)

    The evaluation is conducted through 28 items assessing difficulties in emotional regulation, divided into 5 subscales: lack of control, rejection, interference, inattention, and emotional confusion. Scores range from 1 (almost never) to 5 (almost always), with higher scores being associated with greater difficulties in emotional regulation.

    Measured: Up to 6 months follow-up

  2. EuroQol

    Quality of life is evaluated through 5 items assessing difficulties in mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Scores range from 1 (I do not have problems) to 3 (unable to perform these activities), with higher scores being associated with a worse quality of life.

    Measured: Up to 6 months follow-up

  3. The EuroQol Visual Analog Scale (VAS)

    The EuroQol Visual Analog Scale (VAS) assesses self-reported quality of life using a thermometer scale ranging from 0 (the worst imaginable health state) to 100 (the best imaginable health state).

    Measured: Up to 6 months follow-up

  4. Satisfaction with Treatment Questionnaire (STQ) An adaptation of Client Satisfaction Questionnaire (CSQ-8)

    Our adaptation includes 6 of the 8 items of the CSQ-8 (perceived quality, adequacy to previous expectations, recommendation of the treatment to friends or family, usefulness of the techniques learned, general satisfaction with the intervention and probability that they will choose an intervention of this type again) and one more item related to the discomfort generated by the intervention. Likewise, a change has been made in the Likert response scale from 4 points in the original (0 = "Bad / Not at all" to 4 = "Excellent/Very Much") to 11 in the current one (0 = "Bad / Not at all to 10 = "Excellent/Very Much").

    Measured: Up to 6 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2025
  2. Study start1 Nov 2025 (estimated)
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion1 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
The recruitment process for this study will be conducted within the participating correctional facilities: Brians 1, Brians 2, Quatre Camins, and Lledoners (Barcelona). Inmates who are evaluated in the specialized Mental Health care service at the correctional facility and who have at least one diagnosis of a mental health disorder (TE) will be offered the opportunity to participate. The selection process will be based on the clinical evaluation carried out by the mental health professionals, who will inform the inmates about the possibility of participating in the study and offer them the chance to join, provided they meet the inclusion criteria and give their informed consent.
Masking
None (open label)
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07070531
Sponsor's protocol ID
IPES/PU-CP/2025
Status last verified
Jun 2025
First submitted
30 Apr 2025
Last updated
17 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Under request

Publications

  • Brooks R. EuroQol: the current state of play. Health Policy. 1996 Jul;37(1):53-72. doi: 10.1016/0168-8510(96)00822-6.

    PubMed 10158943
  • Osma J, Martinez-Loredo V, Quilez-Orden A, Peris-Baquero O, Ferreres-Galan V, Prado-Abril J, Torres-Alfosea MA, Rosellini AJ. Multidimensional emotional disorders inventory: Reliability and validity in a Spanish clinical sample. J Affect Disord. 2023 Jan 1;320:65-73. doi: 10.1016/j.jad.2022.09.140. Epub 2022 Sep 29.

    PubMed 36183816
  • Osma J, Quilez-Orden A, Suso-Ribera C, Peris-Baquero O, Norman SB, Bentley KH, Sauer-Zavala S. Psychometric properties and validation of the Spanish versions of the overall anxiety and depression severity and impairment scales. J Affect Disord. 2019 Jun 1;252:9-18. doi: 10.1016/j.jad.2019.03.063. Epub 2019 Mar 29.

    PubMed 30953927
  • Bentley KH, Gallagher MW, Carl JR, Barlow DH. Development and validation of the Overall Depression Severity and Impairment Scale. Psychol Assess. 2014 Sep;26(3):815-830. doi: 10.1037/a0036216. Epub 2014 Apr 7.

    PubMed 24708078
  • Peris-Baquero O, Osma J, Gil-LaCruz M, Martinez-Garcia L. Acceptability of and intention to use the Unified Protocol delivered in group format in the Spanish Public Health System. J Eval Clin Pract. 2021 Dec;27(6):1299-1309. doi: 10.1111/jep.13546. Epub 2021 Feb 9.

    PubMed 33565231
  • Osma J, Peris-Baquero O, Suso-Ribera C, Farchione TJ, Barlow DH. Effectiveness of the Unified Protocol for transdiagnostic treatment of emotional disorders in group format in Spain: Results from a randomized controlled trial with 6-months follow-up. Psychother Res. 2022 Mar;32(3):329-342. doi: 10.1080/10503307.2021.1939190. Epub 2021 Jun 16.

    PubMed 34132170
  • Barlow DH, Harris BA, Eustis EH, Farchione TJ. The unified protocol for transdiagnostic treatment of emotional disorders. World Psychiatry. 2020 Jun;19(2):245-246. doi: 10.1002/wps.20748. No abstract available.

    PubMed 32394551
  • Sakiris N, Berle D. A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based intervention. Clin Psychol Rev. 2019 Aug;72:101751. doi: 10.1016/j.cpr.2019.101751. Epub 2019 Jun 25.

    PubMed 31271848
  • Cassiello-Robbins C, Southward MW, Tirpak JW, Sauer-Zavala S. A systematic review of Unified Protocol applications with adult populations: Facilitating widespread dissemination via adaptability. Clin Psychol Rev. 2020 Jun;78:101852. doi: 10.1016/j.cpr.2020.101852. Epub 2020 Apr 20.

    PubMed 32360953
  • Carlucci L, Saggino A, Balsamo M. On the efficacy of the unified protocol for transdiagnostic treatment of emotional disorders: A systematic review and meta-analysis. Clin Psychol Rev. 2021 Jul;87:101999. doi: 10.1016/j.cpr.2021.101999. Epub 2021 Mar 9.

    PubMed 34098412

Questions about this trial

What is this clinical trial studying?

A study testing Unified Protocol in people with Depression Disorders and Anxiety, run by Instituto de Investigación Sanitaria Aragón at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Óscar Peris Baquero, Phd (978645386 ext. +34, operis@unizar.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Structured interview for anxiety disorders and related disorders, according to the DSM-5 (ADIS-5) (time frame: Only before of the treatment to check inclusion criteria). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07070531, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in